Navigation Links
EnzySurge, Maker of DermaStream(TM), Completes Funding Round of US$4 Million
Date:6/2/2008

Proceeds Will be Used to Accelerate Market Entry of its Wound Care Products

RICHMOND, Virginia and ROSH HA'AYIN, Israel, June 2 /PRNewswire/ -- EnzySurge Ltd. (EnzySurge), a provider of innovative solutions for advanced chronic wound management, announced today that it successfully completed its latest round of funding of US $4 million. The round was extended from $2 million, as was announced on January 2008, to $4 million and was led by Eli Gilboa from Gilboa&Licht, who is the company's chairman. To date, the company has raised a total US$7.3 million. With this additional capital, the company will be positioned to execute on its plan to commercialize its products, for market launch in early 2009. The addressable market for DermaStream(TM) advanced wound care products is estimated by industry analysts to be US$6 billion.

EnzySurge's DermaStream(TM) product line is based on its proprietary Continuous Streaming Therapy (CST(TM)) technology. The comprehensive system continuously streams a fresh supply of active solutions to a controlled wound environment. EnzySurge has developed a series of bio-active therapeutic solutions to facilitate safe and effective healing of chronic wounds through all phases, from debridement, through regeneration to closure. The DermaStream family of products is designed to treat all forms of chronic wounds including diabetic ulcers, venous ulcers and pressure ulcers. DermaStream touch-free treatments result in faster, more effective and painless wound healing in the hospital, clinics and at home.

EnzySurge is currently completing the 2nd phase of a multi-centered, double blind clinical trial focused on chronic leg ulcers (venous ulcers). The intermediate results of the trial indicate a significant improvement and acceleration in treatment.

"I am very excited about the results of our most recent clinical trials and the feedback we are receiving since initiating our marketing activities in the US," says Amir Shiner, CEO of EnzySurge. "This latest funding round is a great vote of confidence from our investors. The funds will enable us to carry out plans to complete the transition from an R&D focused organization to the marketing and business development phase of our company. We are focused on the final steps in commercialization of our products, completing the regulatory process and preparing for market launch in early 2009."

Shiner adds: "We recently opened a US headquarter office in Virginia which will manage the US operations, with focus on a disciplined market launch, increasing market penetration, and establishing strategic partnerships. We have also recently completed a branding process and have launched our new Web site http://www.dermastream.com. We are experiencing a growing interest from leading players in the wound care market."

About EnzySurge

EnzySurge Ltd. is a developer and provider of innovative solutions for the treatment and management of chronic wounds. EnzySurge's flagship DermaStream(TM) platform based on the proprietary Continuous Streaming Therapy (CST(TM)) offers a new and unique wound treatment modality by continuously streaming a fresh supply of advanced therapeutic solutions to a controlled wound environment. DermaStream(TM) is designed to deliver effective, affordable and easy-to-use wound treatment throughout all phases of chronic wound treatment from debridement, through regeneration to wound closure. DermaStream(TM) is intended for use in hospitals, clinics and for home care.

EnzySurge is committed to the development and delivery of innovative solutions that improve the quality of life of chronic-wound patients by shortening healing time, preventing hospitalization and reducing treatment costs. For more information, please visit our web site http://www.dermastream.com.

PR Contacts:

Boaz Gruener, Director of Marketing and Business Development

boazg@dermastream.com

+972-54-4563608


'/>"/>
SOURCE EnzySurge Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EnzySurge, Maker of DermaStream(TM), Establishes a US Office in the Virginia Biotech Commercialization Center
2. Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
3. Ortho Evra Patch Makers Settling Cases
4. New research shows that iPods do not interfere with cardiac pacemakers
5. Bioscience Group Warns Policymakers Against Complacency
6. BSP Pharma Inc., Makers of FlexNow(TM) Joint Formula Sign Distribution Deal with Vitamin Shoppe and GNC
7. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
8. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
9. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
10. BioMarin to Present at the BioCentury NewsMakers Conference
11. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma ... Tom Perkins as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, ... Perkins joins Pennside after more than a decade with leading market research firm, ...
(Date:2/21/2017)... Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today ... ended December 31, 2016. SQI is a ... that develops and commercializes proprietary technologies and products for advanced ... ... achieved in fiscal 2016," said Andrew Morris , SQI,s ...
(Date:2/21/2017)... ... February 21, 2017 , ... Cancer diagnostics workflow solution provider ... executive team to lead the development and commercialization of its Cancer Information Data ... diagnosis and treatment of cancer. The CIDT addresses the need for curated and ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... transformative design and manufacturing solutions for original equipment manufacturers (OEMs) , today announced ... marks Creation Technologies’ third consecutive year winning in its category of electronics manufacturing ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its quarter and year ended December 31, 2016. ... million compared to $6.9 million in the same quarter last ... $0.6 million compared to $2.6 million in the fourth quarter ... was $0.5 million, or $0.02 per diluted share, which compares ...
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
Breaking Biology News(10 mins):